These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 31077304)

  • 21. Coevolution between bacterial CRISPR-Cas systems and their bacteriophages.
    Watson BNJ; Steens JA; Staals RHJ; Westra ER; van Houte S
    Cell Host Microbe; 2021 May; 29(5):715-725. PubMed ID: 33984274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CRISPR/Cas systems in genome engineering of bacteriophages].
    Liang CJ; Meng FM; Ai YC
    Yi Chuan; 2018 May; 40(5):378-389. PubMed ID: 29785946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural insights into the inactivation of the type I-F CRISPR-Cas system by anti-CRISPR proteins.
    Yang L; Zhang Y; Yin P; Feng Y
    RNA Biol; 2021 Nov; 18(sup2):562-573. PubMed ID: 34606423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins.
    Bondy-Denomy J; Garcia B; Strum S; Du M; Rollins MF; Hidalgo-Reyes Y; Wiedenheft B; Maxwell KL; Davidson AR
    Nature; 2015 Oct; 526(7571):136-9. PubMed ID: 26416740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral diversity threshold for adaptive immunity in prokaryotes.
    Weinberger AD; Wolf YI; Lobkovsky AE; Gilmore MS; Koonin EV
    mBio; 2012 Dec; 3(6):e00456-12. PubMed ID: 23221803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-CRISPR proteins: Counterattack of phages on bacterial defense (CRISPR/Cas) system.
    Chaudhary K; Chattopadhyay A; Pratap D
    J Cell Physiol; 2018 Jan; 233(1):57-59. PubMed ID: 28247934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems.
    Davidson AR; Lu WT; Stanley SY; Wang J; Mejdani M; Trost CN; Hicks BT; Lee J; Sontheimer EJ
    Annu Rev Biochem; 2020 Jun; 89():309-332. PubMed ID: 32186918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species.
    Pawluk A; Staals RH; Taylor C; Watson BN; Saha S; Fineran PC; Maxwell KL; Davidson AR
    Nat Microbiol; 2016 Jun; 1(8):16085. PubMed ID: 27573108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-canonical inhibition strategies and structural basis of anti-CRISPR proteins targeting type I CRISPR-Cas systems.
    Yin P; Zhang Y; Yang L; Feng Y
    J Mol Biol; 2023 Apr; 435(7):167996. PubMed ID: 36754343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phage AcrIIA2 DNA Mimicry: Structural Basis of the CRISPR and Anti-CRISPR Arms Race.
    Liu L; Yin M; Wang M; Wang Y
    Mol Cell; 2019 Feb; 73(3):611-620.e3. PubMed ID: 30606466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Biology of CRISPR-Cas: Backward and Forward.
    Hille F; Richter H; Wong SP; Bratovič M; Ressel S; Charpentier E
    Cell; 2018 Mar; 172(6):1239-1259. PubMed ID: 29522745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR-Cas10 assisted editing of virulent staphylococcal phages.
    Nayeemul Bari SM; Hatoum-Aslan A
    Methods Enzymol; 2019; 616():385-409. PubMed ID: 30691652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Holding a grudge: persisting anti-phage CRISPR immunity in multiple human gut microbiomes.
    Mick E; Stern A; Sorek R
    RNA Biol; 2013 May; 10(5):900-6. PubMed ID: 23439321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural insights into the inactivation of CRISPR-Cas systems by diverse anti-CRISPR proteins.
    Zhu Y; Zhang F; Huang Z
    BMC Biol; 2018 Mar; 16(1):32. PubMed ID: 29554913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Anti-CRISPR Story: A Battle for Survival.
    Maxwell KL
    Mol Cell; 2017 Oct; 68(1):8-14. PubMed ID: 28985512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structures and Strategies of Anti-CRISPR-Mediated Immune Suppression.
    Wiegand T; Karambelkar S; Bondy-Denomy J; Wiedenheft B
    Annu Rev Microbiol; 2020 Sep; 74():21-37. PubMed ID: 32503371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covalent Modifications of the Bacteriophage Genome Confer a Degree of Resistance to Bacterial CRISPR Systems.
    Liu Y; Dai L; Dong J; Chen C; Zhu J; Rao VB; Tao P
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32938767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical Anti-CRISPR Locus Repression by a Bi-functional Cas9 Inhibitor.
    Osuna BA; Karambelkar S; Mahendra C; Sarbach A; Johnson MC; Kilcher S; Bondy-Denomy J
    Cell Host Microbe; 2020 Jul; 28(1):23-30.e5. PubMed ID: 32325051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
    Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
    Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CRISPR-Associated Proteins Are Crucial Repressors of Anti-CRISPR Transcription.
    Stanley SY; Borges AL; Chen KH; Swaney DL; Krogan NJ; Bondy-Denomy J; Davidson AR
    Cell; 2019 Sep; 178(6):1452-1464.e13. PubMed ID: 31474367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.